Everest Medicines has unveiled key advancements in its proprietary AI-driven mRNA platform at its 2025 R&D Day in Shanghai. 

The company showcased three core programs developed through this platform—personalized cancer vaccine EVM16, off-the-shelf cancer vaccine EVM14, and its in vivo CAR-T program—demonstrating significant momentum in its strategy to drive internal innovation. 

The AI+mRNA platform integrates Everest’s proprietary neoantigen prediction algorithm (EVER-NEO-1), third-generation mRNA sequence optimization, and advanced lipid nanoparticle (LNP) delivery technologies. These tools enable the creation of highly targeted, potent immunotherapies.

EVM16 is a personalized cancer vaccine designed to stimulate specific T-cell responses based on each patient’s tumor profile. Early clinical data show it produces strong immune responses, even at low doses. The first patient in the trial was dosed in March 2025. 

EVM14, a pre-formulated mRNA vaccine targeting five tumor-associated antigens, has received FDA IND clearance and is moving toward trials in China. It aims to prevent tumor recurrence in several types of squamous cell carcinomas and will be evaluated in a global Phase 1 study starting Q3 2025.